Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Synthesis and biological evaluation of [18F]fluorovinpocetine, a potential PET radioligand for TSPO imaging.

Nag S, Krasikova R, Airaksinen AJ, Arakawa R, Petukhovd M, Gulyas B.

Bioorg Med Chem Lett. 2019 Jun 20. pii: S0960-894X(19)30417-2. doi: 10.1016/j.bmcl.2019.06.037. [Epub ahead of print]

PMID:
31257082
2.

Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid.

Jakobsson U, Mäkilä E, Airaksinen AJ, Alanen O, Etilé A, Köster U, Ranjan S, Salonen J, Santos HA, Helariutta K.

Contrast Media Mol Imaging. 2019 Mar 12;2019:3728563. doi: 10.1155/2019/3728563. eCollection 2019.

3.

Recycling of 18O enriched water used in 18F cyclotron production.

Todorov B, Belovezhdova I, Alanen O, Airaksinen AJ, Djingova R.

Appl Radiat Isot. 2019 Mar;145:109-115. doi: 10.1016/j.apradiso.2018.12.013. Epub 2018 Dec 11.

PMID:
30593937
4.

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.

5.

Radiolabeled Molecular Imaging Probes for the In Vivo Evaluation of Cellulose Nanocrystals for Biomedical Applications.

Imlimthan S, Otaru S, Keinänen O, Correia A, Lintinen K, Santos HA, Airaksinen AJ, Kostiainen MA, Sarparanta M.

Biomacromolecules. 2019 Feb 11;20(2):674-683. doi: 10.1021/acs.biomac.8b01313. Epub 2018 Nov 9.

PMID:
30380842
6.

Efficient cartridge purification for producing high molar activity [18F]fluoro-glycoconjugates via oxime formation.

Keinänen O, Partelová D, Alanen O, Antopolsky M, Sarparanta M, Airaksinen AJ.

Nucl Med Biol. 2018 Dec;67:27-35. doi: 10.1016/j.nucmedbio.2018.10.001. Epub 2018 Oct 15.

PMID:
30380464
7.

Comparison of 68Ga-DOTA-Siglec-9 and 18F-Fluorodeoxyribose-Siglec-9: Inflammation Imaging and Radiation Dosimetry.

Virtanen H, Silvola JMU, Autio A, Li XG, Liljenbäck H, Hellberg S, Siitonen R, Ståhle M, Käkelä M, Airaksinen AJ, Helariutta K, Tolvanen T, Veres TZ, Saraste A, Knuuti J, Jalkanen S, Roivainen A.

Contrast Media Mol Imaging. 2017 Dec 31;2017:7645070. doi: 10.1155/2017/7645070. eCollection 2017.

8.

Multimodality Imaging of Silica and Silicon Materials In Vivo.

Karaman DŞ, Sarparanta MP, Rosenholm JM, Airaksinen AJ.

Adv Mater. 2018 Jun;30(24):e1703651. doi: 10.1002/adma.201703651. Epub 2018 Feb 1. Review.

PMID:
29388264
9.

Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models.

Keinänen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M.

EJNMMI Res. 2017 Dec 2;7(1):95. doi: 10.1186/s13550-017-0344-6.

10.

Drug-Loaded Multifunctional Nanoparticles Targeted to the Endocardial Layer of the Injured Heart Modulate Hypertrophic Signaling.

Ferreira MPA, Ranjan S, Kinnunen S, Correia A, Talman V, Mäkilä E, Barrios-Lopez B, Kemell M, Balasubramanian V, Salonen J, Hirvonen J, Ruskoaho H, Airaksinen AJ, Santos HA.

Small. 2017 Sep;13(33). doi: 10.1002/smll.201701276. Epub 2017 Jul 17.

PMID:
28714245
11.

Pretargeted PET Imaging of trans-Cyclooctene-Modified Porous Silicon Nanoparticles.

Keinänen O, Mäkilä EM, Lindgren R, Virtanen H, Liljenbäck H, Oikonen V, Sarparanta M, Molthoff C, Windhorst AD, Roivainen A, Salonen JJ, Airaksinen AJ.

ACS Omega. 2017 Jan 31;2(1):62-69. doi: 10.1021/acsomega.6b00269. Epub 2017 Jan 6.

12.

Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Nov;24(11):2033. doi: 10.1038/mt.2016.196. No abstract available.

13.

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Erratum in: Mol Ther. 2016 Nov;24(11):2033.

14.

In vitro and in vivo assessment of heart-homing porous silicon nanoparticles.

Ferreira MP, Ranjan S, Correia AM, Mäkilä EM, Kinnunen SM, Zhang H, Shahbazi MA, Almeida PV, Salonen JJ, Ruskoaho HJ, Airaksinen AJ, Hirvonen JT, Santos HA.

Biomaterials. 2016 Jul;94:93-104. doi: 10.1016/j.biomaterials.2016.03.046. Epub 2016 Apr 11.

PMID:
27107168
15.

A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging.

Keinänen O, Li XG, Chenna NK, Lumen D, Ott J, Molthoff CF, Sarparanta M, Helariutta K, Vuorinen T, Windhorst AD, Airaksinen AJ.

ACS Med Chem Lett. 2015 Dec 10;7(1):62-6. doi: 10.1021/acsmedchemlett.5b00330. eCollection 2016 Jan 14.

16.

Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques.

Rinne P, Hellberg S, Kiugel M, Virta J, Li XG, Käkelä M, Helariutta K, Luoto P, Liljenbäck H, Hakovirta H, Gardberg M, Airaksinen AJ, Knuuti J, Saraste A, Roivainen A.

Mol Imaging Biol. 2016 Feb;18(1):99-108. doi: 10.1007/s11307-015-0873-1.

PMID:
26122428
17.

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A.

Cancer Immunol Res. 2015 Aug;3(8):915-25. doi: 10.1158/2326-6066.CIR-14-0220-T. Epub 2015 May 14.

18.

Multifunctional porous silicon nanoparticles for cancer theranostics.

Wang CF, Sarparanta MP, Mäkilä EM, Hyvönen ML, Laakkonen PM, Salonen JJ, Hirvonen JT, Airaksinen AJ, Santos HA.

Biomaterials. 2015 Apr;48:108-18. doi: 10.1016/j.biomaterials.2015.01.008. Epub 2015 Feb 11.

PMID:
25701036
19.

Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.

Yrjölä S, Sarparanta M, Airaksinen AJ, Hytti M, Kauppinen A, Pasonen-Seppänen S, Adinolfi B, Nieri P, Manera C, Keinänen O, Poso A, Nevalainen TJ, Parkkari T.

Eur J Pharm Sci. 2015 Jan 25;67:85-96. doi: 10.1016/j.ejps.2014.11.003. Epub 2014 Nov 14.

PMID:
25447744
20.

Oxidative stress protection by exogenous delivery of rhHsp70 chaperone to the retinal pigment epithelium (RPE), a possible therapeutic strategy against RPE degeneration.

Subrizi A, Toropainen E, Ramsay E, Airaksinen AJ, Kaarniranta K, Urtti A.

Pharm Res. 2015 Jan;32(1):211-21. doi: 10.1007/s11095-014-1456-6. Epub 2014 Jul 17.

PMID:
25030185
21.

In vivo evaluation of porous silicon and porous silicon solid lipid nanocomposites for passive targeting and imaging.

Kallinen AM, Sarparanta MP, Liu D, Mäkilä EM, Salonen JJ, Hirvonen JT, Santos HA, Airaksinen AJ.

Mol Pharm. 2014 Aug 4;11(8):2876-86. doi: 10.1021/mp500225b. Epub 2014 Jul 9.

PMID:
24977922
22.

Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications.

Santos HA, Mäkilä E, Airaksinen AJ, Bimbo LM, Hirvonen J.

Nanomedicine (Lond). 2014 Apr;9(4):535-54. doi: 10.2217/nnm.13.223. Review.

PMID:
24787441
23.

Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo.

Kallinen A, Todorov B, Kallionpää R, Bäck S, Sarparanta M, Raki M, García-Horsman JA, Bergström KA, Wallén EA, Männistö PT, Airaksinen AJ.

Eur J Med Chem. 2014 May 22;79:436-45. doi: 10.1016/j.ejmech.2014.04.014. Epub 2014 Apr 12.

PMID:
24763264
24.

Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography.

Li XG, Helariutta K, Roivainen A, Jalkanen S, Knuuti J, Airaksinen AJ.

Nat Protoc. 2014 Jan;9(1):138-45. doi: 10.1038/nprot.2013.170. Epub 2013 Dec 19.

PMID:
24356772
25.

Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.

Wang CF, Mäkilä EM, Kaasalainen MH, Liu D, Sarparanta MP, Airaksinen AJ, Salonen JJ, Hirvonen JT, Santos HA.

Biomaterials. 2014 Jan;35(4):1257-66. doi: 10.1016/j.biomaterials.2013.10.065. Epub 2013 Nov 7.

PMID:
24211082
26.

SPECT/CT imaging of radiolabeled cubosomes and hexosomes for potential theranostic applications.

Nilsson C, Barrios-Lopez B, Kallinen A, Laurinmäki P, Butcher SJ, Raki M, Weisell J, Bergström K, Larsen SW, Østergaard J, Larsen C, Urtti A, Airaksinen AJ, Yaghmur A.

Biomaterials. 2013 Nov;34(33):8491-503. doi: 10.1016/j.biomaterials.2013.07.055. Epub 2013 Aug 7.

PMID:
23932247
27.

Radiosynthesis and evaluation of new α1-adrenoceptor antagonists as PET radioligands for brain imaging.

Airaksinen AJ, Finnema SJ, Balle T, Varnäs K, Bang-Andersen B, Gulyás B, Farde L, Halldin C.

Nucl Med Biol. 2013 Aug;40(6):747-54. doi: 10.1016/j.nucmedbio.2013.05.007. Epub 2013 Jun 27.

PMID:
23810488
28.

Translating the concept of peptide labeling with 5-deoxy-5-[18F]fluororibose into preclinical practice: 18F-labeling of Siglec-9 peptide for PET imaging of inflammation.

Li XG, Autio A, Ahtinen H, Helariutta K, Liljenbäck H, Jalkanen S, Roivainen A, Airaksinen AJ.

Chem Commun (Camb). 2013 May 7;49(35):3682-3684. doi: 10.1039/c3cc40738a. Epub 2013 Mar 27.

PMID:
23536117
29.

Amine modification of thermally carbonized porous silicon with silane coupling chemistry.

Mäkilä E, Bimbo LM, Kaasalainen M, Herranz B, Airaksinen AJ, Heinonen M, Kukk E, Hirvonen J, Santos HA, Salonen J.

Langmuir. 2012 Oct 2;28(39):14045-54. doi: 10.1021/la303091k. Epub 2012 Sep 20.

PMID:
22967052
30.

Cellular interactions of surface modified nanoporous silicon particles.

Bimbo LM, Sarparanta M, Mäkilä E, Laaksonen T, Laaksonen P, Salonen J, Linder MB, Hirvonen J, Airaksinen AJ, Santos HA.

Nanoscale. 2012 May 21;4(10):3184-92. doi: 10.1039/c2nr30397c. Epub 2012 Apr 16.

PMID:
22508528
31.

Evaluation of the physicochemical and biopharmaceutical properties of fluoro-indomethacin.

Mori MM, Airaksinen AJ, Hirvonen JT, Santos HA, Caramella CM.

Curr Drug Metab. 2013 Jan;14(1):80-9.

PMID:
22497567
32.

SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I.

Rajecki M, Sarparanta M, Hakkarainen T, Tenhunen M, Diaconu I, Kuhmonen V, Kairemo K, Kanerva A, Airaksinen AJ, Hemminki A.

PLoS One. 2012;7(3):e32871. doi: 10.1371/journal.pone.0032871. Epub 2012 Mar 7.

33.

The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems.

Sarparanta MP, Bimbo LM, Mäkilä EM, Salonen JJ, Laaksonen PH, Helariutta AM, Linder MB, Hirvonen JT, Laaksonen TJ, Santos HA, Airaksinen AJ.

Biomaterials. 2012 Apr;33(11):3353-62. doi: 10.1016/j.biomaterials.2012.01.029. Epub 2012 Jan 29.

PMID:
22285465
34.

Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.

Sarparanta M, Bimbo LM, Rytkönen J, Mäkilä E, Laaksonen TJ, Laaksonen P, Nyman M, Salonen J, Linder MB, Hirvonen J, Santos HA, Airaksinen AJ.

Mol Pharm. 2012 Mar 5;9(3):654-63. doi: 10.1021/mp200611d. Epub 2012 Feb 1.

PMID:
22277076
35.

Quantification of the neurokinin 1 receptor ligand [¹¹C]R116301.

Wolfensberger SP, Maruyama K, van Berckel BN, Lubberink M, Airaksinen AJ, Boellaard R, Luurtsema G, Reddingius W, Janssens FE, Veltman DJ, Windhorst AD, Leysen JE, Lammertsma AA.

Nucl Med Commun. 2011 Oct;32(10):896-902. doi: 10.1097/MNM.0b013e328347e96f.

PMID:
21876400
36.

¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography.

Sarparanta M, Mäkilä E, Heikkilä T, Salonen J, Kukk E, Lehto VP, Santos HA, Hirvonen J, Airaksinen AJ.

Mol Pharm. 2011 Oct 3;8(5):1799-806. doi: 10.1021/mp2001654. Epub 2011 Sep 7.

PMID:
21875120
37.

Multifunctional porous silicon for therapeutic drug delivery and imaging.

Santos HA, Bimbo LM, Lehto VP, Airaksinen AJ, Salonen J, Hirvonen J.

Curr Drug Discov Technol. 2011 Sep;8(3):228-49. Review.

PMID:
21291407
38.

Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats.

Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Mäkilä E, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J, Salonen J.

ACS Nano. 2010 Jun 22;4(6):3023-32. doi: 10.1021/nn901657w.

PMID:
20509673
39.

Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.

Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A.

Clin Cancer Res. 2009 Sep 1;15(17):5396-403. doi: 10.1158/1078-0432.CCR-08-2571. Epub 2009 Aug 25.

40.

First evaluation of [11C]R116301 as an in vivo tracer of NK1 receptors in man.

Wolfensberger SP, van Berckel BN, Airaksinen AJ, Maruyama K, Lubberink M, Boellaard R, Carey WD, Reddingius W, Veltman DJ, Windhorst AD, Leysen JE, Lammertsma AA.

Mol Imaging Biol. 2009 Jul-Aug;11(4):241-5. doi: 10.1007/s11307-009-0204-5. Epub 2009 Mar 31.

41.

[18F]flumazenil binding to central benzodiazepine receptor studies by PET--quantitative analysis and comparisons with [11C]flumazenil.

Odano I, Halldin C, Karlsson P, Varrone A, Airaksinen AJ, Krasikova RN, Farde L.

Neuroimage. 2009 Apr 15;45(3):891-902. doi: 10.1016/j.neuroimage.2008.12.005. Epub 2008 Dec 24.

PMID:
19136064
42.

[11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors.

Airaksinen AJ, Nag S, Finnema SJ, Mukherjee J, Chattopadhyay S, Gulyás B, Farde L, Halldin C.

Bioorg Med Chem. 2008 Jul 1;16(13):6467-73. doi: 10.1016/j.bmc.2008.05.039. Epub 2008 May 20.

43.

Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study.

Takano A, Halldin C, Varrone A, Karlsson P, Sjöholm N, Stubbs JB, Schou M, Airaksinen AJ, Tauscher J, Gulyás B.

Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):630-6. Epub 2007 Nov 14.

PMID:
18000665
44.

Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2.

Takano A, Gulyás B, Varrone A, Karlsson P, Schou M, Airaksinen AJ, Vandenhende F, Tauscher J, Halldin C.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):153-7. Epub 2007 Oct 2.

PMID:
17909794
45.

Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand.

Airaksinen AJ, Jablonowski JA, van der Mey M, Barbier AJ, Klok RP, Verbeek J, Schuit R, Herscheid JD, Leysen JE, Carruthers NI, Lammertsma AA, Windhorst AD.

Nucl Med Biol. 2006 Aug;33(6):801-10.

PMID:
16934699
46.

Synthesis and biological evaluation of 6/7-exo-methyl-3beta-(4-iodo)phenyltropane-2beta-carboxylic acid methyl esters.

Airaksinen AJ, Huotari M, Shvetsov A, Vainiotalo P, Männisto PT, Tuomisto L, Bergström KA, Vepsäläinen J.

Eur J Med Chem. 2005 Mar;40(3):299-304. Epub 2005 Jan 7.

PMID:
15725499
47.

One-pot synthesis of 3,4-disubstituted 1H-pyrroles from 2-tropanones.

Airaksinen AJ, Ahlgren M, Vepsäläinen J.

J Org Chem. 2002 Jul 12;67(14):5019-21.

PMID:
12098329

Supplemental Content

Loading ...
Support Center